Venrock

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to repair damaged tissues and improve organ function. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate tissue regeneration in a variety of organs. Its key programs include SZN-043, which aims to promote hepatocyte regeneration in liver diseases, and SZN-1326, designed to repair diseased epithelial tissue for patients with inflammatory bowel disease. Surrozen's research targets several disease areas, including conditions affecting the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system, by engaging the body’s natural biological repair mechanisms. The company was incorporated in 2015 and continues to advance its innovative therapeutic approaches.

Auditoria.AI, Inc., founded in 2019 and based in Santa Clara, California, specializes in providing technology-driven financial solutions for enterprise accounting and auditing. The company leverages advanced artificial intelligence and machine learning to enhance compliance and streamline finance operations. Its flagship product utilizes natural language processing and predictive analytics to automate back-office processes, minimizing friction and repetition for finance teams. By focusing on automation, Auditoria.AI aims to deliver real-time insights that empower organizations to improve efficiency and decision-making in their financial operations.

Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

Adverum Biotechnologies is a clinical-stage gene therapy company focused on developing innovative treatments for ocular and rare diseases. Headquartered in Redwood City, California, the company aims to establish gene therapy as a new standard of care, aspiring to provide functional cures that restore vision and prevent blindness. Its pipeline includes several product candidates, notably ADVM-022, which targets wet age-related macular degeneration through a single intravitreal injection designed to deliver long-term therapeutic effects. Other candidates include ADVM-043 for alpha-1 antitrypsin deficiency and ADVM-053 for hereditary angioedema. Adverum collaborates with partners like Editas Medicine and Regeneron Pharmaceuticals to leverage advanced AAV vectors and develop treatments for various inherited retinal diseases and ocular therapeutic targets. Founded in 2006, the company was previously known as Avalanche Biotechnologies and rebranded in 2016.

SmithRx is a San Francisco-based company that designs and manages customized pharmacy benefit plans for employers, aiming to enhance employee guidance and satisfaction. Founded in 2016, SmithRx operates on a modern technology platform that emphasizes transparency, efficiency, and data analytics. The company provides a cost-competitive pharmacy benefit management (PBM) model, featuring a pass-through pricing structure, a unified technology system, and high-quality service assurances. Its in-house team combines expertise from various healthcare and technology sectors, including experience from notable companies, to deliver exceptional support and clinical programs. SmithRx focuses on empowering its clients with maximum flexibility and control over their pharmacy benefits, ultimately helping to reduce drug spending and improve the management of prescription benefits. The company's name reflects its commitment to precision and craftsmanship in the pharmacy benefits industry.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, the company focuses on discovering and developing therapies for metabolic diseases, including obesity and diabetes. Carmot employs a proprietary drug discovery approach known as Chemotype Evolution, which enables the exploration of novel chemical and biological frontiers. The company is advancing a portfolio of clinical-stage drug candidates, including CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist; CT-996, a once-daily oral GLP-1 receptor agonist; and CT-868, a once-daily injectable dual GLP-1/GIP receptor agonist for treating type 1 diabetes in patients with overweight or obesity. These innovative therapies aim to enhance glucose clearance and promote weight loss, addressing the fundamental causes of metabolic diseases.

Vocera Communications, Inc. specializes in providing secure and integrated communication and workflow solutions tailored for mobile workers across various sectors, including healthcare, hospitality, retail, energy, and education. The company’s offerings enhance communication and operational efficiency by integrating with existing clinical systems, such as electronic health records and nurse call systems. Vocera's product suite includes the Vocera Communication and Workflow System, which connects various communication devices, including hands-free and voice-controlled options, and the Vocera Care Experience software, designed to improve patient care quality and streamline manual tasks. Additionally, Vocera operates the Experience Innovation Network, collaborating with healthcare organizations to develop innovative solutions that improve patient and care team experiences. The company, founded in 2000 and headquartered in San Jose, California, serves approximately 1,700 healthcare facilities globally, including hospitals and clinics, and distributes its products through direct sales, resellers, and distributors.

Apogee Therapeutics is a biotechnology company based in San Francisco, California, founded in 2022. The company focuses on developing differentiated biologics for the treatment of immunological and inflammatory disorders, specifically targeting atopic dermatitis and chronic obstructive pulmonary disease. Apogee Therapeutics aims to address high unmet medical needs by advancing novel therapies that utilize advanced antibody engineering to enhance therapeutic properties such as half-life. The company's key programs, APG777 and APG808, are designed to leverage established mechanisms of action to improve treatment outcomes for patients suffering from these conditions.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

Dgraph Labs, Inc. is a technology company based in San Francisco, California, that specializes in developing and operating a graph database. Founded in 2016, Dgraph offers a low-latency solution designed for efficient retrieval of structured data, catering to both small startups and large enterprises. Its flagship product, Slash Enterprise, is a fully-managed and serverless solution that supports terabytes of data and operates on dedicated, multi-zone clusters across major cloud platforms such as AWS, Azure, and GCP. The company's graph database is particularly suited for real-time user queries and addresses various use cases, including semantic search, pattern matching, and fraud detection, enabling clients to effectively manage, represent, and visualize large datasets.

The Public Health Company is focused on creating a global biosecurity platform that offers a Software as a Service (SaaS) solution for managing bio-risks within enterprises. Founded in 2020 and headquartered in Palo Alto, California, the company combines expert knowledge with advanced technology to provide a comprehensive approach to enterprise risk management. Its platform addresses various physical world threats, delivering actionable and predictive intelligence that enables dynamic risk management with exceptional speed and scale. The Public Health Company serves businesses, healthcare providers, and public health systems, positioning itself as a key player in enhancing public health and safety through innovative solutions.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

SmithRx is a San Francisco-based company that designs and manages customized pharmacy benefit plans for employers, aiming to enhance employee guidance and satisfaction. Founded in 2016, SmithRx operates on a modern technology platform that emphasizes transparency, efficiency, and data analytics. The company provides a cost-competitive pharmacy benefit management (PBM) model, featuring a pass-through pricing structure, a unified technology system, and high-quality service assurances. Its in-house team combines expertise from various healthcare and technology sectors, including experience from notable companies, to deliver exceptional support and clinical programs. SmithRx focuses on empowering its clients with maximum flexibility and control over their pharmacy benefits, ultimately helping to reduce drug spending and improve the management of prescription benefits. The company's name reflects its commitment to precision and craftsmanship in the pharmacy benefits industry.

Decodable is a data integration and engineering platform focused on serverless streaming data, founded in 2021 and based in San Francisco, California. The company provides software that enables applications and data engineers to construct complex data pipelines efficiently. Its platform facilitates quick connections to various messaging, storage, and database systems, allowing users to collect, process, and deliver data effectively to both offline and online systems.

Atom Computing Inc. is a company based in Berkeley, California, that focuses on manufacturing scalable quantum computers utilizing individual atoms. Founded in 2018, the company harnesses the quantum mechanical properties of atoms to process information and address complex problems that traditional computers cannot solve. Atom Computing's technology allows for the optical control, scaling, and stabilization of these atoms, facilitating efficient quantum calculations in various fields, including drug design, computational chemistry, and general computing. Through its innovative approach, Atom Computing aims to advance the development of quantum technology and expand its applications across multiple industries.

Apogee Therapeutics is a biotechnology company based in San Francisco, California, founded in 2022. The company focuses on developing differentiated biologics for the treatment of immunological and inflammatory disorders, specifically targeting atopic dermatitis and chronic obstructive pulmonary disease. Apogee Therapeutics aims to address high unmet medical needs by advancing novel therapies that utilize advanced antibody engineering to enhance therapeutic properties such as half-life. The company's key programs, APG777 and APG808, are designed to leverage established mechanisms of action to improve treatment outcomes for patients suffering from these conditions.

Skyryse, Inc. is an air mobility company founded in 2016 and headquartered in El Segundo, California. The company specializes in the development of helicopters and aircraft, targeting sectors such as emergency services, public transport, and urban planning. Skyryse has created a comprehensive hardware and software operating system known as FlightOS. This system provides a unified interface for pilots, allowing them to operate various types of aircraft, both rotorcraft and fixed-wing, using the same controls. By significantly reducing pilot fatigue and complexity, FlightOS enhances flight safety and improves emergency management. With just a few hours of training, any pilot can effectively fly any aircraft, whether from the cockpit or remotely, making aviation more accessible and efficient.

Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

Atom Computing Inc. is a company based in Berkeley, California, that focuses on manufacturing scalable quantum computers utilizing individual atoms. Founded in 2018, the company harnesses the quantum mechanical properties of atoms to process information and address complex problems that traditional computers cannot solve. Atom Computing's technology allows for the optical control, scaling, and stabilization of these atoms, facilitating efficient quantum calculations in various fields, including drug design, computational chemistry, and general computing. Through its innovative approach, Atom Computing aims to advance the development of quantum technology and expand its applications across multiple industries.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

The Public Health Company is focused on creating a global biosecurity platform that offers a Software as a Service (SaaS) solution for managing bio-risks within enterprises. Founded in 2020 and headquartered in Palo Alto, California, the company combines expert knowledge with advanced technology to provide a comprehensive approach to enterprise risk management. Its platform addresses various physical world threats, delivering actionable and predictive intelligence that enables dynamic risk management with exceptional speed and scale. The Public Health Company serves businesses, healthcare providers, and public health systems, positioning itself as a key player in enhancing public health and safety through innovative solutions.

TAE Technologies, Inc. is a company focused on developing clean fusion energy through advanced particle accelerator and plasma physics. Founded in 1998 and headquartered in Foothill Ranch, California, with an additional office in Rancho Santa Margarita, TAE Technologies aims to create a new source of energy derived from natural processes that generates no harmful byproducts. With over two decades of research, the company is dedicated to commercializing safe and cost-effective fusion power solutions. TAE Technologies also contributes to advancements in power management, electric mobility, and life sciences, addressing the global energy demand while promoting sustainable and carbon-free energy alternatives.

Auditoria.AI, Inc., founded in 2019 and based in Santa Clara, California, specializes in providing technology-driven financial solutions for enterprise accounting and auditing. The company leverages advanced artificial intelligence and machine learning to enhance compliance and streamline finance operations. Its flagship product utilizes natural language processing and predictive analytics to automate back-office processes, minimizing friction and repetition for finance teams. By focusing on automation, Auditoria.AI aims to deliver real-time insights that empower organizations to improve efficiency and decision-making in their financial operations.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that specializes in targeted DNA integration to develop innovative therapies for severe diseases. The company utilizes a precision gene editing approach to precisely correct genetic mutations, replace malfunctioning genes, and insert therapeutic genetic sequences at specific locations within the genome. Its technology aims to transform treatment paradigms by enabling the targeted integration of genetic payloads, which could potentially cure a range of serious and life-threatening conditions. Graphite Bio was formerly known as Integral Medicines, Inc. before rebranding in August 2020, and it was incorporated in 2019.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Decodable is a data integration and engineering platform focused on serverless streaming data, founded in 2021 and based in San Francisco, California. The company provides software that enables applications and data engineers to construct complex data pipelines efficiently. Its platform facilitates quick connections to various messaging, storage, and database systems, allowing users to collect, process, and deliver data effectively to both offline and online systems.

Artiva Biotherapeutics is a biotech company focused on developing and manufacturing cellular immunotherapies for cancer patients. Founded in 2019 and based in San Diego, California, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating various hematologic cancers and solid tumors. The company's product pipeline targets specific antigens, including CD20 and CD19 for B-cell lymphomas, as well as HER2 for certain solid tumors. Artiva's approach emphasizes the therapeutic potential of NK cells and aims to overcome challenges in scaling and manufacturing these therapies. The company is committed to delivering safe, effective, and readily accessible cell therapies to benefit cancer patients. Artiva operates as a subsidiary of Green Cross Holdings Corporation.

Sitka, Inc. operates an online communication platform that connects patients with healthcare providers across various specialties, including endocrinology, neurology, orthopedics, pulmonology, and rheumatology. Founded in 2018 by experts in healthcare, technology, and policy, the company aims to transform specialty care in the United States by enhancing the capabilities of primary care providers and facilitating patient involvement in their care. The platform allows for personalized consultations, such as interpreting MRI results with board-certified doctors, thereby improving patients' understanding of their health conditions and enabling better decision-making. Headquartered in Carmel, California, Sitka is supported by a range of investors and is dedicated to fostering effective and trusted care delivery for all patients through its innovative solutions.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Luma, Inc. designs and develops a platform for managing events, focusing on both virtual and in-person experiences. Founded in 2020 and based in San Francisco, California, the company offers a range of features, including ticket sales, attendance tracking, and analytics. Luma enables users to host virtual classes, record live shows, and connect with their communities through integrated tools. The platform supports event promotion and management, allowing users to send invitations and accept tips and memberships. Overall, Luma aims to enhance the event-hosting experience by providing a comprehensive suite of services for organizers and attendees alike.

Federation Bio Inc. is focused on developing microbial therapeutics aimed at curing various diseases through the human microbiome. The company utilizes platforms that harness naturally occurring or engineered bacteria, along with a supportive community of bacteria, to promote engraftment and achieve lasting therapeutic responses. Its research encompasses a broad spectrum of conditions, including secondary hyperoxaluria, metabolic disorders, immune diseases, cholestatic diseases, and cancer. Founded in 2018 and headquartered in South San Francisco, California, Federation Bio was previously known as Comet Medicine Inc. before rebranding in April 2019.

Kinnate Biopharma Inc. is a biopharmaceutical company based in San Diego, California, focused on developing small molecule kinase inhibitors for the treatment of genomically defined cancers. Founded in 2018, the company aims to create precision oncology therapeutics to address the needs of underserved patient populations. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is working on KIN003, which targets specific alterations in the FGFR2 and FGFR3 genes, and has other small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor. Kinnate Biopharma employs expertise in structure-based drug discovery and translational research to advance its pipeline of candidates aimed at treating cancers associated with specific oncogenic alterations.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Iris Medicine is a biotechnology company founded in 2019 and based in Palo Alto, California. It specializes in developing novel therapeutics aimed at the pharmaceutical and healthcare sectors. The company's focus is on creating RNA medicines that target serious diseases, particularly those that have limited or no existing treatment options. By advancing these innovative therapies, Iris Medicine seeks to assist medical professionals in effectively managing and treating neurological diseases.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

ABL Space Systems specializes in designing and manufacturing rockets for the launch of small satellites. Incorporated in 2017 and based in El Segundo, California, the company focuses on developing low-cost and reliable launch vehicles, with its primary product being the RS1 rocket. This vehicle is capable of carrying payloads of up to 1,350 kilograms to Low Earth Orbit (LEO) and supports various configurations, including multi-manifest and dedicated deployments. In addition to the RS1, ABL also creates the GS0 ground system, which facilitates rapid deployment and integration of launch operations at multiple sites. The company operates from a 30,000 square foot facility dedicated to research, development, and production, and is privately owned, supported by a group of private equity investors.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Percipient.ai Inc. is an artificial intelligence company that specializes in advanced analytics for national security and intelligence missions. Founded in 2017 and headquartered in Santa Clara, California, with an additional office in Reston, Virginia, the company offers a platform called Mirage. This platform enhances the analysis of full motion video, geo-spatial intelligence, and multi-source intelligence data, helping professionals make informed decisions in critical situations. Mirage includes a module that identifies and contextualizes individuals, objects, and activities, enabling users to rapidly understand unstructured data. By leveraging computer vision and multi-source intelligence, Percipient.ai provides solutions that support both commercial and government clients in their time-sensitive operations, facilitating the real-time exploitation of complex visual and intelligence data.

Simbe Robotics, Inc. is a technology company based in San Francisco, California, specializing in autonomous robotic solutions for the retail industry. Founded in 2014, the company has developed a robotic system named Tally, which autonomously navigates store aisles to conduct shelf audits. Tally captures real-time inventory data, identifying out-of-stock items, low stock levels, misplaced products, and pricing discrepancies. By automating these repetitive and labor-intensive tasks, Simbe Robotics enhances operational efficiency for retail staff, allowing them to focus on customer service and other critical aspects of store management. The robotic system operates safely during regular store hours, effectively integrating into the shopping environment without disrupting customers or employees.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

Concentric Analgesics, Inc. is a biopharmaceutical company dedicated to the discovery and development of non-opioid therapeutics for managing acute and chronic pain. Founded in 2014 and based in San Francisco, the company focuses on creating innovative pain relief solutions that require only a single local administration. Its pipeline includes several promising candidates: CA-008, an injectable prodrug of capsaicin designed for acute post-surgical pain; CA-051, intended for epidural use in treating refractory pain related to cancer or amputation; and an injection product aimed at alleviating chronic pain associated with moderate to severe osteoarthritis. Concentric Analgesics aims to target pain at its source while minimizing systemic exposure, thereby enhancing patient outcomes and simplifying ongoing care.

Biolux Research develops and distributes innovative orthodontic products aimed at improving dental treatment outcomes. The company is known for its flagship devices, OrthoPulse and OsseoPulse. OrthoPulse utilizes low levels of light energy to stimulate the bone surrounding teeth, which may facilitate faster tooth movement and potentially shorten the duration of orthodontic treatments such as braces or clear aligners. OsseoPulse focuses on bone regeneration, enhancing dental procedures. Founded in 2003, Biolux Research is headquartered in Vancouver, Canada, and is dedicated to making orthodontic treatments less invasive and more comfortable through advanced technologies.

Make School Inc. is an educational institution based in San Francisco, California, that offers both in-person courses and online tutorials focused on product development and technology. Founded in 2011, the organization provides a higher education degree program designed to bridge the gap between education and employment for high school graduates. Its curriculum covers essential areas such as computer science theory, application development, web development, open source software, networking, and communication skills. By partnering with established universities, Make School delivers instructional, curricular, and admissions services, ensuring that its educational offerings remain relevant to the modern economy and accessible to students from diverse backgrounds. This approach enables students to effectively prepare for careers as software developers or startup founders.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Skyryse, Inc. is an air mobility company founded in 2016 and headquartered in El Segundo, California. The company specializes in the development of helicopters and aircraft, targeting sectors such as emergency services, public transport, and urban planning. Skyryse has created a comprehensive hardware and software operating system known as FlightOS. This system provides a unified interface for pilots, allowing them to operate various types of aircraft, both rotorcraft and fixed-wing, using the same controls. By significantly reducing pilot fatigue and complexity, FlightOS enhances flight safety and improves emergency management. With just a few hours of training, any pilot can effectively fly any aircraft, whether from the cockpit or remotely, making aviation more accessible and efficient.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Shape Security, Inc. specializes in cybersecurity solutions aimed at protecting web and mobile applications from automated cyber-attacks. Established in 2011 and headquartered in Santa Clara, California, with additional offices in Sydney and London, the company offers products such as ShapeShifter Elements, which enforces real-time security measures, and Shape Protection Manager, a cloud-based management tool for its services. Shape Security has successfully prevented over $1 billion in fraud losses for a diverse range of clients, including major retailers, financial institutions, airlines, and government agencies. Its AI-powered technology effectively mitigates risks associated with fraud, chargebacks, and unauthorized transactions, helping organizations maintain customer trust and protect their reputations against the threats posed by criminal activity.

Atom Computing Inc. is a company based in Berkeley, California, that focuses on manufacturing scalable quantum computers utilizing individual atoms. Founded in 2018, the company harnesses the quantum mechanical properties of atoms to process information and address complex problems that traditional computers cannot solve. Atom Computing's technology allows for the optical control, scaling, and stabilization of these atoms, facilitating efficient quantum calculations in various fields, including drug design, computational chemistry, and general computing. Through its innovative approach, Atom Computing aims to advance the development of quantum technology and expand its applications across multiple industries.

Renew Health, established in 2016 and headquartered in San Francisco, operates a cloud-based platform focused on providing senior benefits tailored for the baby boomer generation. The company addresses inefficiencies in the healthcare system related to medication management, which accounts for a significant portion of healthcare spending. Renew Health aims to align its business model with the interests of health plans and patients by charging fixed fees on a per-member and per-task basis for medication administration. This approach allows the company to pass through drug-related costs and rebates to health plans while also offering clinical services designed to enhance patient outcomes and reduce overall healthcare costs. By prioritizing value for payers and patients, Renew Health seeks to address the misaligned incentives often found in traditional pharmaceutical benefits management.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Doctor On Demand, Inc. is a telemedicine company that provides an online platform for patients to consult with licensed healthcare providers, including doctors and psychologists, through video calls. Established in 2012 and headquartered in San Francisco, California, the company offers a range of medical services addressing conditions such as cold and flu, allergies, anxiety, and chronic illnesses. Its platform, Synapse, caters to health plans and employers, facilitating both on-demand and scheduled visits via smartphones, tablets, or computers. Doctor On Demand emphasizes accessibility and quality care, enabling patients to easily receive medical attention and prescriptions when needed. Additionally, the company has offices in Minneapolis, Minnesota, and Washington, D.C.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

Percipient.ai Inc. is an artificial intelligence company that specializes in advanced analytics for national security and intelligence missions. Founded in 2017 and headquartered in Santa Clara, California, with an additional office in Reston, Virginia, the company offers a platform called Mirage. This platform enhances the analysis of full motion video, geo-spatial intelligence, and multi-source intelligence data, helping professionals make informed decisions in critical situations. Mirage includes a module that identifies and contextualizes individuals, objects, and activities, enabling users to rapidly understand unstructured data. By leveraging computer vision and multi-source intelligence, Percipient.ai provides solutions that support both commercial and government clients in their time-sensitive operations, facilitating the real-time exploitation of complex visual and intelligence data.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Dynamic Signal, established in 2010 and headquartered in San Bruno, California, specializes in employee communication and engagement. Its platform connects companies with their employees, facilitating the dissemination of timely, relevant content across various channels and devices. This enhances productivity, fosters employee engagement, and amplifies corporate messaging. Dynamic Signal serves hundreds of global enterprises, including 85 Fortune 500 companies, such as IBM, Salesforce, and Edelman.

Skyryse, Inc. is an air mobility company founded in 2016 and headquartered in El Segundo, California. The company specializes in the development of helicopters and aircraft, targeting sectors such as emergency services, public transport, and urban planning. Skyryse has created a comprehensive hardware and software operating system known as FlightOS. This system provides a unified interface for pilots, allowing them to operate various types of aircraft, both rotorcraft and fixed-wing, using the same controls. By significantly reducing pilot fatigue and complexity, FlightOS enhances flight safety and improves emergency management. With just a few hours of training, any pilot can effectively fly any aircraft, whether from the cockpit or remotely, making aviation more accessible and efficient.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, dedicated to the development and commercialization of its lead drug candidate, TRC101. This non-absorbed, orally-administered polymer is designed to treat metabolic acidosis, a condition often associated with chronic kidney disease (CKD). Metabolic acidosis can contribute to the progression of CKD and is linked to various health issues such as muscle wasting, loss of bone density, and increased mortality risk. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, aiming to provide an effective treatment option for patients suffering from this condition. The company was founded in 2013 and is focused on addressing the unmet medical needs of individuals with CKD.

Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Evident.io, Inc. is a company focused on cloud security management, offering a software platform that enables continuous monitoring and remediation of risks, vulnerabilities, and compliance for public cloud environments. Founded in 2013 and based in Pleasanton, California, the company provides cloud security services that include resource visibility, vulnerability assessment, and alert notifications. Its flagship product, the Evident Security Platform (ESP), is an agentless and API-centric solution that helps organizations identify and address security misconfigurations and risks across their cloud infrastructure, particularly within Amazon Web Services (AWS). By delivering actionable intelligence in a user-friendly manner, Evident.io aims to facilitate a balance between agility and robust security, catering to a diverse range of industries and organizational sizes. In 2018, the company was acquired by Palo Alto Networks.

Dynamic Signal, established in 2010 and headquartered in San Bruno, California, specializes in employee communication and engagement. Its platform connects companies with their employees, facilitating the dissemination of timely, relevant content across various channels and devices. This enhances productivity, fosters employee engagement, and amplifies corporate messaging. Dynamic Signal serves hundreds of global enterprises, including 85 Fortune 500 companies, such as IBM, Salesforce, and Edelman.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Shape Security, Inc. specializes in cybersecurity solutions aimed at protecting web and mobile applications from automated cyber-attacks. Established in 2011 and headquartered in Santa Clara, California, with additional offices in Sydney and London, the company offers products such as ShapeShifter Elements, which enforces real-time security measures, and Shape Protection Manager, a cloud-based management tool for its services. Shape Security has successfully prevented over $1 billion in fraud losses for a diverse range of clients, including major retailers, financial institutions, airlines, and government agencies. Its AI-powered technology effectively mitigates risks associated with fraud, chargebacks, and unauthorized transactions, helping organizations maintain customer trust and protect their reputations against the threats posed by criminal activity.

Beckon, Inc. offers omnichannel analytics software designed to provide marketers with performance analytics, visualization, and reporting solutions. Founded in 2011 and based in San Mateo, California, the company operates as a subsidiary of Aclate, Inc. Beckon's software-as-a-service platform integrates marketing data to deliver dashboards and scorecards that facilitate cross-channel marketing intelligence. The platform emphasizes data management and visibility into marketing performance, enabling users to analyze their campaigns in real time. It provides automated tools for campaign planning and offers key performance indicators to help marketers optimize their strategies, maximize return on investment, and demonstrate the impact of marketing efforts on overall business outcomes.

Appthority, Inc. specializes in mobile application security solutions, focusing on protecting enterprises from various mobile threats to data and employee privacy. Founded in 2011 and based in San Francisco, the company offers a comprehensive Mobile Threat Protection (MTP) solution that provides threat detection, management, and intelligence. Appthority's software enables organizations to maintain visibility into mobile risks associated with devices, applications, and networks, thereby helping clients safeguard their private data. The company has gained the trust of numerous Fortune 1000 companies due to its effective mobile threat protection and the ability to enhance enterprise visibility and control over mobile security risks. As of November 2018, Appthority operates as a subsidiary of NortonLifeLock Inc.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

Evident.io, Inc. is a company focused on cloud security management, offering a software platform that enables continuous monitoring and remediation of risks, vulnerabilities, and compliance for public cloud environments. Founded in 2013 and based in Pleasanton, California, the company provides cloud security services that include resource visibility, vulnerability assessment, and alert notifications. Its flagship product, the Evident Security Platform (ESP), is an agentless and API-centric solution that helps organizations identify and address security misconfigurations and risks across their cloud infrastructure, particularly within Amazon Web Services (AWS). By delivering actionable intelligence in a user-friendly manner, Evident.io aims to facilitate a balance between agility and robust security, catering to a diverse range of industries and organizational sizes. In 2018, the company was acquired by Palo Alto Networks.

PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Spirox, Inc., based in Menlo Park, California, is a medical device company focused on improving the quality of life for patients with nasal obstruction, particularly those suffering from nasal valve collapse (NVC). Formerly known as Nasoform, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive treatment option for this common yet often undertreated condition. The implant addresses weakened lateral wall cartilage, a significant contributor to nasal airway obstruction. Founded in 2011, Spirox aims to complete product development, secure marketing authorization in the United States, and initiate commercialization efforts to make their innovative solution available to patients. As of July 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

Appthority, Inc. specializes in mobile application security solutions, focusing on protecting enterprises from various mobile threats to data and employee privacy. Founded in 2011 and based in San Francisco, the company offers a comprehensive Mobile Threat Protection (MTP) solution that provides threat detection, management, and intelligence. Appthority's software enables organizations to maintain visibility into mobile risks associated with devices, applications, and networks, thereby helping clients safeguard their private data. The company has gained the trust of numerous Fortune 1000 companies due to its effective mobile threat protection and the ability to enhance enterprise visibility and control over mobile security risks. As of November 2018, Appthority operates as a subsidiary of NortonLifeLock Inc.

Dollar Shave Club is a lifestyle brand and e-commerce company based in Santa Monica, California, established in 2012. It specializes in providing grooming products for men through a subscription model, offering a variety of items such as razors, blades, shave butter, aftershave liquids, face washes, and wipes. The company focuses on delivering smart and affordable products designed to enhance customers' lives. By employing a unique research and development process that incorporates botanicals and chemists, Dollar Shave Club produces its own goods while maintaining competitive pricing.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Cloudflare, Inc. is a San Francisco-based software company that specializes in web performance and security services for businesses globally. It operates a cloud platform that integrates various network services, including security solutions such as Cloud Firewall, Bot Management, and Distributed Denial of Service protection. The company enhances website performance through its Content Delivery Network (CDN) and intelligent routing, while also providing optimization tools for content and images. Furthermore, Cloudflare offers reliability solutions like Load Balancing and DNS services, alongside security features aimed at protecting internal resources through Zero Trust Security and Secure Web Gateway. Its consumer offerings include a DNS resolver and a virtual private network (VPN) designed to secure mobile traffic. Cloudflare serves diverse industries, including technology, healthcare, financial services, and government, and was founded in 2009.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Dynamic Signal, established in 2010 and headquartered in San Bruno, California, specializes in employee communication and engagement. Its platform connects companies with their employees, facilitating the dissemination of timely, relevant content across various channels and devices. This enhances productivity, fosters employee engagement, and amplifies corporate messaging. Dynamic Signal serves hundreds of global enterprises, including 85 Fortune 500 companies, such as IBM, Salesforce, and Edelman.

Doctor On Demand, Inc. is a telemedicine company that provides an online platform for patients to consult with licensed healthcare providers, including doctors and psychologists, through video calls. Established in 2012 and headquartered in San Francisco, California, the company offers a range of medical services addressing conditions such as cold and flu, allergies, anxiety, and chronic illnesses. Its platform, Synapse, caters to health plans and employers, facilitating both on-demand and scheduled visits via smartphones, tablets, or computers. Doctor On Demand emphasizes accessibility and quality care, enabling patients to easily receive medical attention and prescriptions when needed. Additionally, the company has offices in Minneapolis, Minnesota, and Washington, D.C.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company based in South San Francisco, California. It specializes in developing a novel class of antibody therapeutics utilizing its Probody technology platform, which aims to enhance the targeting of tumors while minimizing drug activity in healthy tissues. The company's clinical-stage product candidates include CX-072, a therapeutic targeting programmed cell death ligand 1; CX-2009, a drug conjugate targeting CD166; BMS-986249 and BMS-986288, both targeting CTLA-4 for metastatic melanoma and solid tumors; and CX-2029, a drug conjugate for CD71 in solid tumors. CytomX collaborates strategically with several industry leaders, including AbbVie, Amgen, and Bristol-Myers Squibb, to advance its Probody therapeutics. Founded in 2008, CytomX Therapeutics is committed to providing innovative and less toxic treatment options for patients with severe illnesses such as cancer.

Shift Messenger, Inc. is a San Francisco-based company founded in 2014 that specializes in developing a mobile messaging application for shift workers in sectors such as retail, restaurants, and healthcare. The application facilitates communication among employees, allowing them to swap shifts and manage their schedules effectively. By providing a platform for users to connect with their workplace communities, the app helps shift workers address everyday challenges and stay informed about workplace updates. Through its tools, Shift Messenger aims to enhance the work lives of shift employees and support the development of their professional identities.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.